loss per share 61,418 61,033 61,353 60,996
Condensed Consolidated Balance Sheet Data
September 30, December 31,
in thousands (unaudited)
Cash and investments ** $ 35,487 $ 94,058
assets 100,244 156,208
liabilities 304,033 301,858
equity (203,789) (145,650)
* Other non-operating expense for the three and nine months ended September 30, 2008 principally reflect an unrealized loss resulting from the revaluation of the company's non-current auction rate security investments as of September 30, 2008.
** Cash and investments include cash equivalents, restricted investments and cash equivalents, and non-current investments.
Any statements contained in this presentation that relate to future
plans, events or performance are forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. These
forward-looking statements are subject to a number of risks and
uncertainties that could cause actual results, and the timing of events, to
differ materially from those described in the forward-looking statements.
These risks and uncertainties include, among others, those relating to our
ability to obtain financing and to form collaborative relationships, the
effect of a potential delisting of our common stock from The Nasdaq Global
Market, uncertainty regarding potential future deterioration in the market
for auction rate securities which could negatively affect our cash position
and result in additional permanent impairment charges, our ability to
develop and marke
|SOURCE deCODE genetics Inc|
Copyright©2008 PR Newswire.
All rights reserved